Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
335 participants
OBSERVATIONAL
2017-06-26
2017-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Objectives The primary objective is to evaluate exposure to the flu vaccine in patients with MS during the 2016-17 campaign. Secondary objectives are to evaluate exposure to mandatory vaccines, non mandatory vaccines, in the context of immunoactive treatments; to identify potential limitations to vaccines in general in patients with MS.
Methods Cross-sectional observational multicentric study, performed in Auvergne-Rhône-Alpes (France).
Data will be collected through an auto-questionnaire administered during an out-patient visit or hospitalization, during a two-week period.
Statistical analysis Description of the percentage of patients exposed to the flu vaccine, and to other vaccines. Stratification according to demographics (age, sex) and MS related criteria (disability level, relapse in the year before, disease-modifiying drug) Expected results Vaccine exposure of patients with MS will be put in perspective with the general population exposure. The study can provide information regarding potential reluctance of patients with MS towards vaccines. This could lead to develop specific communication tools for patients with MS and/or health professionals.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of the Modifications of Environmental Exposures and Health Care Access During COVID-19 Lockdown on Multiple Sclerosis
NCT05033782
Study to Investigate the Immune Response and Safety of Prophylactic Vaccines in Patients Treated for Multiple Sclerosis
NCT02275741
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
NCT05197699
Immunisation Status and Safety of Vaccines in Italian MS Patients
NCT04300868
COVID-19 Booster Vaccination in Persons With Multiple Sclerosis
NCT05081271
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MS patients
Single group of patients with MS attending an outpatient MS clinic or hospitalization
Auto-questionnaire
Single Auto-questionnaire administered during or after a consultation/hospitalization
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Auto-questionnaire
Single Auto-questionnaire administered during or after a consultation/hospitalization
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 and more
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sandra VUKUSIC
Role: PRINCIPAL_INVESTIGATOR
Hôpital Neurologique Pierre Wertheimer - GHE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hôpital Neurologique Pierre Wertheimer
Bron, , France
Service de Neurologie - Hôpital G. Montpied
Clermont-Ferrand, , France
Service de Neurologie - CHU de Grenoble
Grenoble, , France
Service de Neurologie - Hôpital Saint Joseph Saint Luc
Lyon, , France
Cabinet de Neurologie - Clinique de la Sauvegarde
Lyon, , France
Service de Neurologie - Hôpital Nord - CHU St Etienne
Saint-Etienne, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL17_0169
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.